89Zr-Girentuximab
TLX250CDx-CP-001
Phase 3 small_molecule completed
Quick answer
89Zr-Girentuximab for Clear Cell Renal Cell Carcinoma is a Phase 3 program (small_molecule) at Telix Pharmaceuticals Ltd with 2 ClinicalTrials.gov record(s).
Program details
- Company
- Telix Pharmaceuticals Ltd
- Indication
- Clear Cell Renal Cell Carcinoma
- Phase
- Phase 3
- Modality
- small_molecule
- Status
- completed